Holen Sie sich die Stockscreener-App
2.34
3.08%
0.07
Schlusskurs vom Vortag:
$2.27
Offen:
$2.23
24-Stunden-Volumen:
74,054
Relative Volume:
0.98
Marktkapitalisierung:
$23.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.64M
KGV:
-0.5355
EPS:
-4.3698
Netto-Cashflow:
$-33.40M
1W Leistung:
+23.16%
1M Leistung:
-4.88%
6M Leistung:
-56.38%
1J Leistung:
-83.04%
1-Tages-Spanne:
$2.17
$2.3791
1-Wochen-Bereich:
$1.82
$2.3791
52-Wochen-Spanne:
$1.70
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.34 | 18.96M | 0 | -37.64M | -33.40M | -4.3698 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
ATOS Maintained by Ascendiant Capital -- Price Target Raised to $25 - GuruFocus
Ascendiant Capital maintains Buy rating on Atossa Therapeutics, $25 price target - TradingView
Atossa plans shareholder stake in potential PRV proceeds - Yahoo Finance
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – HAN:YAG - TradingView
Atossa Therapeutics plans stapled CVR issue tied to potential rare pediatric disease voucher - Traders Union
Atossa Therapeutics, Inc. Revenue Breakdown – HAN:YAG - TradingView
Atossa to Issue CVRs Giving Shareholders 25% of Voucher Proceeds - Minichart
Atossa plans CVR issuance tied to priority review voucher - Investing.com
Atossa plans CVR issuance tied to priority review voucher By Investing.com - Investing.com South Africa
Atossa Therapeutics Introduces CVR Plan for Voucher Upside - TipRanks
Atossa Therapeutics, Inc. (ATOS) Plans CVR Paying Up To $50M From Potential PRV - TradingView
Atossa CEO to join Harvard panel on aging disea... - Pluang
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging - PR Newswire
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Salinas Californian
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) dropped from S&P Global BMI Index - marketscreener.com
Atossa posts updated corporate presentation highlighting (Z)-Endoxifen programs, $26.1M cash - TradingView
Debt to equity ratio of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBIT forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Atossa Therapeutics (ATOS) Holds Steady at $2.52 — Awaiting Catalyst Within $2.39–$2.65 RangeTPO Profile - siam.in
Atossa Therapeutics (ATOS) Q2 2026 Earnings: Narrower-than-Expected Loss Reflects Cost ContainmentPositive Surprise Momentum - dars.gov.et
Atossa Therapeutics explores collaborative clinical research for (Z)-endoxifen applications - Traders Union
Atossa (ATOS) Results Breakdown: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: Shares Rise 2.76% at the CloseEarnings Power Value - vinanet.vn
Atossa Therapeutics advances investigational Z-endoxifen research for broader DMD applications - Traders Union
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - Sahm
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
ATOS: Multiple Catalysts Converge in 2H26 - Smartkarma
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Atossa Therapeutics pursues ESR1 mutation research to tackle endocrine resistance in breast cancer - Traders Union
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Atossa Therapeutics shifts clinical focus to pre-surgical breast cancer patients - Traders Union
Atossa Therapeutics (ATOS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock SlipsQuarterly Profit Report - dars.gov.et
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Atossa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Q2 net loss, financing and (Z)-endoxifen Phase 2 progress - TradingView
Atossa Therapeutics reports Q2 2026 results, ad... - Pluang
Atossa Therapeutics (ATOS) Dips 2.48% to $2.36 as Stock Tests Key Support ZoneWyckoff Upthrust - dars.gov.et
Atossa Therapeutics Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView
Atossa Therapeutics investigates (Z)-endoxifen for McCune-Albright syndrome and endocrine disorders - tradersunion.com
Atossa Therapeutics (ATOS) Advances Clinical Pipeline Amid Valua - GuruFocus
Form 8K Atossa Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
Atossa Therapeutics Q2 net loss widens on lower interest income - TradingView
Atossa Therapeutics reports Q2 2026 net loss $8.5M, cash $26.1M; advances (Z)-endoxifen programs - TradingView
ATOS: Q2 2026 net loss was $8.5M; (Z)-endoxifen programs advanced and $4.5M in new capital raised - TradingView
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary - TradingView
Atossa Therapeutics (NASDAQ: ATOS) posts $18.1M loss, flags going concern risk - Stock Titan
Atossa Therapeutics strengthens pipeline with new data on Z-endoxifen breast cancer therapy - tradersunion.com
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
Atossa Therapeutics founder to be selected as NIAID director — report - Endpoints News
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):